The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Targeted therapy for early-stage lung cancer
Jay Lee, MD, The Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, discusses targeted therapy in early-stage lung cancer. Currently, the only approved targeted therapy in the early-stage setting is osimertanib, which was approved based on the results of the Phase III ADAURA (NCT02511106) trial. Currently, clinical trials, including the Phase II NAUTIKA1 (NCT04302025) trial, are exploring targeted therapies in early-stage lung cancer in the perioperative space in the neoadjuvant setting. Dr Lee additionally discusses the challenges associated with next-generation sequencing (NGS) tissue testing in the perioperative space, including turnaround time and obtaining tissue during biopsy that is adequate for NGS testing. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
